共 50 条
- [21] A PHASE 1A/1B DOSE-ESCALATION STUDY OF INTRAVENOUSLY ADMINISTERED SB 11285 ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A7 - A8Abbas, A.Strauss, J.Janku, F.Karim, R.Olszanski, A.Luke, J. J.Leach, K.Iyer, R.
- [22] Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumorsInvestigational New Drugs, 2023, 41 : 380 - 390Anastasios StathisAnthony W. TolcherJudy S. WangDaniel J. RenoufLin-Chi ChenLeah H. SuttnerTomoko FreshwaterAndrea L. WebberTapan NayakLillian L. Siu
- [23] Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burdenJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (08) : 1 - 11Schenker, MichaelBurotto, MauricioRichardet, MartinCiuleanu, Tudor-EliadeGoncalves, AnthonySteeghs, NeeltjeSchoffski, PatrickAscierto, Paolo A.Maio, MicheleLugowska, IwonaLupinacci, LorenaLeary, AlexandraDelord, Jean-PierreGrasselli, JulietaTan, David S. P.Friedmann, JenniferVuky, JacquelineTschaika, MarinaKonduru, SomasekharVemula, Sai VikramSlepetis, RutaKollia, GeorgiaPacius, MisenaDuong, QuyenHuang, NingDoshi, ParulBaden, JonathanDi Nicola, Massimo
- [24] Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumorsINVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 380 - 390Stathis, AnastasiosTolcher, Anthony W.Wang, Judy S.Renouf, Daniel J.Chen, Lin-ChiSuttner, Leah H.Freshwater, TomokoWebber, Andrea L.Nayak, TapanSiu, Lillian L.
- [25] Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumoursInvestigational New Drugs, 2012, 30 : 1962 - 1971Tanja TrarbachBeate SchultheisThomas C. GaulerVesile SchneiderDirk StrumbergWilfried E. E. EberhardtStephanie Le ScouillerMarcelo MarottiKathryn H. BrownJoachim Drevs
- [26] Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumoursINVESTIGATIONAL NEW DRUGS, 2012, 30 (05) : 1962 - 1971Trarbach, TanjaSchultheis, BeateGauler, Thomas C.Schneider, VesileStrumberg, DirkEberhardt, Wilfried E. E.Le Scouiller, StephanieMarotti, MarceloBrown, Kathryn H.Drevs, Joachim
- [27] An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Harrington, Kevin JosephRullan, AntonioDeighton, LouiseBarata, JoaoCastro, HenryAhlers, Christoph MatthiasMcrae, JohnBommareddy, PraveenCoffin, Robert S.Middleton, Mark R.
- [28] A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid TumorsONCOLOGIST, 2019, 24 (07): : 891 - +Ma, YuxiangFang, WenfengZhang, YangYang, YunpengHong, ShaodongZhao, YuanyuanTendolkar, AmolChen, LuXu, DongShing, JenniferZhao, HongyunZhang, Li
- [29] An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Dasari, ArvindKauh, John S.Tucci, ChristopherNanda, ShivaniKania, Marek K.Carlisle, Jennifer W.Paulson, Andrew Scott
- [30] A Multicenter, Open-Label, Phase 1 Study Evaluating the Safety and Tolerability of Pegaspargase in Combination with Gemcitabine in Advanced Metastatic Solid Tumors and LymphomaCANCER INVESTIGATION, 2015, 33 (05) : 172 - 179Borad, Mitesh J.Babiker, Hani M.Anthony, StephenMita, MonicaBuchbinder, AbyKeilani, TahaGrem, Jean